TAVR sales hit $1B as company shifts focus to structural heart
Edwards Lifesciences (NYSE: EW) saw its stock climb 6% to $75.68 following Q4 earnings that exceeded expectations.
Key Financials:
- Revenue: $1.386B (+9.4% YoY)
- Profit: $385.6M (+4.2%)
- EPS: 59¢ (4¢ above estimates)
Growth Drivers:
- TAVR sales: $1.04B (+6%)
- TMTT (Mitral & Tricuspid): $352M (+78%)
- New Asymptomatic TAVR Indication: Expected mid-2025
- JenaValve Acquisition: Anticipated FDA approval for aortic regurgitation this year
“With three key growth areas—TAVR, mitral and tricuspid, and emerging structural heart therapies—we’re well positioned for continued strong performance,” said CEO Bernard Zovighian.
Follow MEDWIRE.AI for the latest in cardiac innovations.
